Volume 1, Supplement 2, December 2000

Selective angiotensin receptor blockade: Clinical effects today for the promise of improved outcomes tomorrow

SUPPLEMENTNew basic science initiatives with the angiotensin II receptor blocker valsartan
Marc de Gasparo

POPULAR
TOPICSUPPLEMENTAngiotensin receptor blocker selectivity at the AT₁- and AT₂-receptors: conceptual and clinical effects
Thomas Unger, Steffen Sandmann

SUPPLEMENTHypertension and its management: a problem in need of new treatment strategies
Joel M Neutel

POPULAR
TOPICSUPPLEMENTValsartan and the renin-angiotensin-aldosterone system: blood pressure control and beyond
Björn Dahlöf

SUPPLEMENTSaving lives: long-term morbidity and mortality trials with selective angiotensin receptor blocker therapy
Gordon T McInnes

SUPPLEMENTCardiac, renal and vascular complications in the diabetic patient
Alberto Zanchetti

POPULAR
TOPICSUPPLEMENTImproving the prognosis of diabetic patients: evaluating the role of intensive versus moderate blood pressure control with selective angiotensin II receptor blocker (ARB) therapy
Martin P Bedigian

SUPPLEMENTNew clinical investigations with selective angiotensin II receptor blocker therapy in diabetes and renal disease
Luis M Ruilope

SUPPLEMENTThe HF epidemic: the need for new treatment strategies
Peter E Carson

SUPPLEMENTPathological involvement of chymase-dependent angiotensin II formation in the development of cardiovascular disease
Hidenori Urata

POPULAR
TOPICSUPPLEMENTRationale for angiotensin II receptor blocker therapy in chronic heart failure
Jay N Cohn

POPULAR
TOPICSUPPLEMENTWill more complete inhibition of the RAAS with angiotensin receptor blockade improve survival following myocardial infarction?
Marc A Pfeffer